Market Overview - The medical device sector experienced a decline of 0.74% on December 29, with Huakang Clean leading the drop [1] - The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1] Top Performers - Meihao Medical (301363) saw a closing price of 25.04, with an increase of 8.30% and a trading volume of 197,100 shares, totaling a transaction value of 482 million yuan [1] - Mailande (688273) closed at 41.73, up 8.22%, with a trading volume of 55,200 shares and a transaction value of 227 million yuan [1] - Kangzhong Medical (688607) closed at 45.80, up 7.23%, with a trading volume of 40,200 shares and a transaction value of 180 million yuan [1] Underperformers - Huakang Clean (301235) closed at 39.21, down 8.54%, with a trading volume of 123,300 shares and a transaction value of 488 million yuan [2] - C Jianxin (688805) closed at 47.16, down 7.26%, with a trading volume of 89,000 shares and a transaction value of 426 million yuan [2] - Furuim Medical (300049) closed at 71.93, down 4.20%, with a trading volume of 66,800 shares and a transaction value of 485 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 565 million yuan from institutional investors, while retail investors experienced a net inflow of 328 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Meihao Medical (301363) had a net outflow of 54.30 million yuan from institutional investors, with retail investors also showing a net outflow of 0.76 million yuan [3] - Jigaofazhan (600807) experienced a net inflow of 44.75 million yuan from institutional investors, while retail investors had a net outflow of 61.29 million yuan [3] - Kangzhong Medical (688626) saw a net inflow of 44.26 million yuan from institutional investors, with retail investors showing a slight net outflow [3]

Core Viewpoint - Zhijiang Biological announced the appointment of Zhonghui Certified Public Accountants as the auditing firm for the company's 2025 financial statements and internal controls, with changes in the assigned auditors due to personnel adjustments [1] Group 1 - Zhonghui Certified Public Accountants will provide auditing services for the 2025 fiscal year [1] - Liu Muyong was originally appointed as the project partner, with Wang Xuefen and Liu Muyong as signing auditors, and Wu Xiaohui as the quality control reviewer [1] - Due to Wang Xuefen's departure from Zhonghui and internal adjustments, Zhu Qi has been appointed as the signing auditor, and Shi Weicen as the quality control reviewer [1]

证券代码：688317 证券简称：之江生物 公告编号：2025-069 上海之江生物科技股份有限公司 关于变更签字注册会计师及项目质量控制复核人的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海之江生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开第五届董事会第十三次会议，并于 2025 年 5 月 15 日召开 2024 年年度股 东大会，审议通过了《关于续聘 2025 年度审计机构的议案》，同意公司续聘中 汇会计师事务所（以下简称"中汇"）作为公司 2025 年度审计机构，聘期一年。 具体内容详见公司于 2025 年 4 月 25 日在上海证券交易所网站（www.sse.com.cn） 刊载披露的《关于续聘 2025 年度会计师事务所的公告》（公告编号：2025-028）。 近日，公司收到中汇出具的《关于变更签字会计师及质量控制复核人的告知 函》，现就具体情况公告如下： 一、本次签字会计师及质量控制复核人变更情况 中汇为公司 2025 年度财务报表和内部控制的审计机构，原委派刘木 ...

Core Viewpoint - Zhijiang Bio's Japanese smart manufacturing project is progressing smoothly and has not been directly affected by changes in the external policy environment [1] Group 1: Project Status - The Japanese smart manufacturing project is being advanced in an orderly manner [1] - The company is closely monitoring the dynamics of Sino-Japanese relations and regional situations [1] Group 2: Operational Principles - The company adheres to principles of prudent operation and risk control during project decision-making and implementation [1] - Future evaluations and responses will be based on changes in the situation to ensure smooth project progress and protect shareholder interests [1]

Core Insights - The article highlights the acceleration of business development (BD) activities in the medical device sector from September to November 2025, with a total of 58 transactions identified across various subfields, including cardiovascular, nuclear medicine, and AI-enabled devices [2][3][4]. Group 1: Mergers and Acquisitions - Mergers and acquisitions have become a prominent form of BD, with companies leveraging capital control and product integration for rapid market positioning [7][8]. - Notable acquisitions include HeartLink's $680 million all-stock acquisition of Micro-Invasive Cardiology, enhancing its structural heart disease and rhythm management capabilities [7]. - Hua'an Zhonghui's acquisition of Bangni Medical marks its entry into the absorbable suture market, indicating a shift in surgical instrument competition towards material innovation [7]. Group 2: Strategic Collaborations - Strategic partnerships have been formed during the China International Import Expo, with companies like Shanghai Pharmaceuticals collaborating with international giants such as Boston Scientific and Medtronic to enhance their supply chain and academic promotion systems [7][8]. - The collaboration between GuoYao Medical and BDI Medical aims to deepen market penetration in the biomedicine and medical device sectors, focusing on compliance and distribution channel construction [13]. Group 3: Cross-Border Cooperation - Cross-border transactions have become more active, with foreign companies establishing local R&D and production systems in China, while domestic firms are exporting their solutions globally [9][10]. - The partnership between Trasis SA and Beijing Pait Biotechnology to establish a joint venture reflects a trend towards localized production and phased integration in the Chinese market [12]. Group 4: Ecosystem Building and Channel Expansion - The integration of supply chains and ecosystem building is a key theme, with companies focusing on collaborative agreements to enhance their market presence [11][15]. - The collaboration between Baxter and Neusoft Medical aims to create a comprehensive surgical solution by integrating their respective technologies [12]. Group 5: AI and Smart Healthcare - AI and data-driven approaches are becoming central to BD collaborations, with companies increasingly focusing on smart healthcare solutions [16][17]. - The partnership between Kefu Medical and Tencent Cloud to develop AI-powered hearing aids exemplifies the trend of integrating technology into healthcare products [21]. Group 6: Research and Diagnostic Synergy - The frequency of research-oriented collaborations is rising, indicating a shift from manufacturing-driven to research-driven industry dynamics [18][19]. - The collaboration between BGI and Infinera to enhance clinical applications of sequencing technology highlights the growing importance of research in driving innovation in the medical device sector [21].

Core Viewpoint - Zhijiang Biological announced on an interactive platform that as of September 30, 2025, the total number of shareholders will be 14,435 [2] Summary by Category - **Company Information** - Zhijiang Biological has confirmed that the total number of shareholders is projected to reach 14,435 by September 30, 2025 [2] - **Investor Communication** - The company engaged with investors through an interactive platform, providing transparency regarding shareholder numbers [2]

Core Points - The company, Zhijiang Biology, announced the signing of a "Four-Party Supervision Agreement for Special Fund Storage" on December 9, which involves the establishment of a special fund account at China Merchants Bank for the "Japanese Intelligent Manufacturing Project" [1] Group 1 - The agreement includes the company, its wholly-owned subsidiary Chuan Yue Co., Ltd., China Merchants Bank, and Guotai Junan Securities [1] - The special fund account will be exclusively used for the allocation and utilization of funds related to the investment project [1]

证券代码：688317 证券简称：之江生物 公告编号：2025-068 上海之江生物科技股份有限公司 关于开立募集资金专户并签订募集资金专户监管协 议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 募集资金基本情况 上海之江生物科技股份有限公司（以下简称"公司"）首次公开发行股票并 在科创板上市的注册申请于 2020 年 11 月 27 日经中国证券监督管理委员会同意 注册（证监许可[2020]3214 号《关于同意上海之江生物科技股份有限公司首次 公开发行股票注册的批复》）。公司获准向社会公开发行人民币普通股（A 股） 股票 4,867.6088 万股，每股发行价格人民币 43.22 元，募集资金合计 210,378.05 万元，扣除发行费用后，实际募集资金净额为 194,232.16 万元。上述募集资金 到位情况已经中汇会计师事务所（特殊普通合伙）审验，并由其出具《验资报告》 （中汇会验[2021]第 0039 号）。 二、 募集资金专户的开立情况及《募集资金专户存储四方监管协议》的签 订情况 乙方：招商 ...

Core Viewpoint - The company has successfully raised a total of 2.104 billion yuan through its initial public offering, with a net amount of 1.942 billion yuan allocated for specific projects [1] Fundraising and Management - The company has established a dedicated account at China Merchants Bank for the management of the raised funds, specifically for the "Japan Intelligent Manufacturing Project" [1] - A four-party supervision agreement has been signed among the company, its wholly-owned subsidiary Chuan Yue Co., Ltd., China Merchants Bank, and Guotai Junan Securities to regulate the use of the funds [1] - As of November 28, 2025, the balance in the dedicated account is reported to be 0 USD/0 JPY [1] - The agreement outlines detailed responsibilities, fund usage supervision, and information inquiry protocols among the parties involved [1]

上海之江生物科技股份有限公司 关于 2025 年第三次以集中竞价交易方式回购公司股份 的进展公告 证券代码：688317 证券简称：之江生物 公告编号：2025-067 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，应当在每个月的前 3 个交易日内公告截至上月末 的回购进展情况。现将公司回购股份进展情况公告如下： 2025 年 11 月，公司通过上海证券交易所交易系统以集中竞价交易方式累计 回购公司股份 1,093,704 股，占公司当前总股本 192,157,999 股的比例为 0.57%， 回购成交的最高价为 22.86 元/股，最低价为 21.52 元/股，支付的资金总额为人 民币 24,160,914.13 元（不含印花税、交易佣金等交易费用）。 截至 2025 年 11 月 28 日，公司通过上海证券交易所交易系统以集中竞价交易 方式累计回购公司股份 1,093,704 股，占公司当前总股本 192, ...